

*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated November 10, 2015 (the “**Prospectus**”) issued by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (the “**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is made pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation by any person to acquire, purchase or subscribe for securities.*

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered, sold or delivered in the United States except pursuant to Rule 144A or an exemption from registration requirements under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The Hong Kong Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. The Offer Shares have not been and will not be registered under the U.S. Securities Act and may not be offered, sold, pledged or transferred within the United States. There is not and it is not currently intended for there to be any public offering of securities of the Company in the United States.*



康宁

**Wenzhou Kangning Hospital Co., Ltd.**

**温州康宁医院股份有限公司**

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2120)**

**STABILIZATION ACTIONS AND  
END OF STABILIZATION PERIOD**

**STABILIZATION ACTIONS AND END OF STABILIZATION PERIOD**

The Company further announces that the stabilization period in connection with the Global Offering ended on December 13, 2015, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilization actions undertaken by the Stabilizing Manager during the stabilization period involved:

- (1) over-allocations of an aggregate of 2,640,000 H Shares in the International Offering, representing 15% of the Offer Shares initially offered under the Global Offering; and
- (2) the full exercise of the Over-allotment Option by the Joint Global Coordinators (on behalf of the International Underwriters), on December 4, 2015 (after trading hours), in respect of an aggregate of 2,640,000 H Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering, to facilitate the delivery of H Shares to a cornerstone investor who has agreed to a delayed delivery of H Shares it subscribed under its cornerstone investment agreement.

## **STABILIZATION ACTIONS AND END OF STABILIZATION PERIOD**

The Company announces that, pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the stabilization period in connection with the Global Offering ended on December 13, 2015, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

The stabilization actions undertaken by the Stabilizing Manager during the stabilization period involved:

- (1) over-allocations of an aggregate of 2,640,000 H Shares in the International Offering, representing 15% of the Offer Shares initially offered under the Global Offering; and
- (2) the full exercise of the Over-allotment Option by the Joint Global Coordinators (on behalf of the International Underwriters), on December 4, 2015 (after trading hours), in respect of an aggregate of 2,640,000 H Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering, to facilitate the delivery of H Shares to a cornerstone investor who has agreed to a delayed delivery of H Shares it subscribed under its cornerstone investment agreement. Details of the full exercise of the Over-allotment Option were disclosed in the Company's announcement dated December 4, 2015.

By order of the Board of Directors of  
**Wenzhou Kangning Hospital Co., Ltd.**  
**Guan Weili**  
*Chairman*

Zhejiang, the PRC, December 14, 2015

*As of the date of this announcement, the executive Directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive Directors are Mr. YANG Yang and Ms. HE Xin; and the independent non-executive Directors are Mr. CHONG Yat Keung, Mr. HUANG Zhi and Mr. WONG Raymond Fook Lam.*